INAMRINONE LACTATE

Details

Stereochemistry	UNKNOWN
Molecular Formula	C10H9N3O.C3H6O3
Molecular Weight	277.2759
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0
Stereo Comments	LACTATE

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)C(O)=O.NC1=CC(=CNC1=O)C2=CC=NC=C2

InChI

InChIKey=DOSIONJFGDSKCQ-UHFFFAOYSA-N

InChI=1S/C10H9N3O.C3H6O3/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7;1-2(4)3(5)6/h1-6H,11H2,(H,13,14);2,4H,1H3,(H,5,6)

HIDE SMILES / InChI

Molecular Formula	C3H6O3
Molecular Weight	90.0779
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	C10H9N3O
Molecular Weight	187.198
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB01427
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/inamrinone.html

Inamrinone (Amrinone) is a positive inotropic cardiotonic with vasodilator properties, phosphodiesterase inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell. Inamrinone is a phosphodiesterase inhibitor (PDE3), resulting in increased cAMP and cGMP which leads to an increase in the calcium influx like that caused by beta-agonists resulting in increased inotropic effect. Inamrinone is used in the treatment of congestive heart failure.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Phosphodiesterase 3A 7 Target ID: CHEMBL241 Sources: http://www.drugbank.ca/drugs/DB01427	Inhibitor 8297	16.7 µM [IC50]
Phosphodiesterase 3B 8 Target ID: CHEMBL290 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10644042	Inhibitor 8297	31.2 µM [IC50]
platelet aggregation 76 Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14698653	Inhibitor 8297	61.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Congestive heart failure 54 Sources: https://www.drugs.com/pro/inamrinone.html	Primary		Approved 8429	AMRINONE LACTATE Approved Use For the short-term management of congestive heart failure. Launch Date 2000

C_max

Value	Dose	Co-administered	Analyte	Population
5.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513658/	0.75 mg/kg 3 times / day steady-state, intravenous dose: 0.75 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		INAMRINONE plasma	Homo sapiens population: UNKNOWN age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
245 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513658/	0.75 mg/kg 3 times / day steady-state, intravenous dose: 0.75 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		INAMRINONE plasma	Homo sapiens population: UNKNOWN age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513658/	0.75 mg/kg 3 times / day steady-state, intravenous dose: 0.75 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		INAMRINONE plasma	Homo sapiens population: UNKNOWN age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
198 ug/kg/min 1 times / day single, intravenous (max) Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 n = 1 Health Status: unhealthy Condition: heart failure Age Group: 0.208333333333333 Sex: F Population Size: 1 Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	Other AEs: Cardiac arrest... Other AEs: Cardiac arrest Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
198 ug/kg/min 1 times / day single, intravenous (max) Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 n = 1 Health Status: unhealthy Condition: heart failure Age Group: 0.208333333333333 Sex: F Population Size: 1 Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	Other AEs: Death... Other AEs: Death (grade 5) Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	Disc. AE: Pulmonary edema, Cardiac arrest... AEs leading to discontinuation/dose reduction: Pulmonary edema Cardiac arrest Respiratory distress syndrome Chest pain Palpitations Ventricular ectopic beats Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
200 mg 3 times / day multiple, oral Highest studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	unhealthy, 53 n = 32 Health Status: unhealthy Condition: congestive heart failure Age Group: 53 Sex: M+F Population Size: 32 Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	Disc. AE: Diarrhea, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Diarrhea Thrombocytopenia Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/
5.8 mg/kg/day 1 times / day multiple, intravenous (mean) Recommended Dose: 5.8 mg/kg/day, 1 times / day Route: intravenous Route: multiple Dose: 5.8 mg/kg/day, 1 times / day Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456	unhealthy, 59.4 (37-81) n = 43 Health Status: unhealthy Condition: congestive heart failure Age Group: 59.4 (37-81) Sex: M+F Population Size: 43 Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456	Disc. AE: Thrombocytopenia... AEs leading to discontinuation/dose reduction: Thrombocytopenia (18.6%) Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456
3 mg/kg 1 times / day single, intravenous (max) Recommended Dose: 3 mg/kg, 1 times / day Route: intravenous Route: single Dose: 3 mg/kg, 1 times / day Sources: https://www.nature.com/articles/pr1984440	unhealthy, <1 n = 6 Health Status: unhealthy Condition: pulmonary hypertension Age Group: <1 Sex: M+F Population Size: 6 Sources: https://www.nature.com/articles/pr1984440	Sources: https://www.nature.com/articles/pr1984440

AEs

AE	Significance	Dose	Population
Cardiac arrest		198 ug/kg/min 1 times / day single, intravenous (max) Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 n = 1 Health Status: unhealthy Condition: heart failure Age Group: 0.208333333333333 Sex: F Population Size: 1 Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
Death	grade 5	198 ug/kg/min 1 times / day single, intravenous (max) Overdose Dose: 198 ug/kg/min, 1 times / day Route: intravenous Route: single Dose: 198 ug/kg/min, 1 times / day Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017	unhealthy, 0.208333333333333 n = 1 Health Status: unhealthy Condition: heart failure Age Group: 0.208333333333333 Sex: F Population Size: 1 Sources: https://link.springer.com/article/10.2165/00128415-199505560-00017
Cardiac arrest	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Chest pain	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Palpitations	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Pulmonary edema	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Respiratory distress syndrome	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Ventricular ectopic beats	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/	unhealthy, 49 n = 13 Health Status: unhealthy Condition: congestive heart failure Age Group: 49 Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/6683463/
Diarrhea	Disc. AE	200 mg 3 times / day multiple, oral Highest studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	unhealthy, 53 n = 32 Health Status: unhealthy Condition: congestive heart failure Age Group: 53 Sex: M+F Population Size: 32 Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/
Thrombocytopenia	Disc. AE	200 mg 3 times / day multiple, oral Highest studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/	unhealthy, 53 n = 32 Health Status: unhealthy Condition: congestive heart failure Age Group: 53 Sex: M+F Population Size: 32 Sources: https://pubmed.ncbi.nlm.nih.gov/3886191/
Thrombocytopenia	18.6% Disc. AE	5.8 mg/kg/day 1 times / day multiple, intravenous (mean) Recommended Dose: 5.8 mg/kg/day, 1 times / day Route: intravenous Route: multiple Dose: 5.8 mg/kg/day, 1 times / day Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456	unhealthy, 59.4 (37-81) n = 43 Health Status: unhealthy Condition: congestive heart failure Age Group: 59.4 (37-81) Sex: M+F Population Size: 43 Sources: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-0633	http://www.3bsc.com/index/pro_info.php?id=19989
3B Scientific (Wuhan) Corp	3B1-00216	http://www.3bsc.com/index/pro_info.php?id=20428
AEchem Scientific Corp., USA	AE044729	http://www.aechemsc.com/info_products/AE044729.php
AHH Chemical co.,ltd	API-1603	http://www.ahhchemical.com/product/API-1603.html
AHH Chemical co.,ltd	MT-00030	http://www.ahhchemical.com/product/MT-00030.html
AK Scientific, Inc. (AKSCI)	868269	http://www.aksci.com/item_detail.php?cat=868269
Acadechem	ACDS-033154	http://www.acadechemical.com/product/107853
Achemo Scientific Limited	AC-16677	http://www.achemo.com/search/?Keyword= 60719-84-8
Achemtek	0104-017105	http://www.achemtek.com/60719-84-8
Alfa Chemistry	AP60719848	https://reagents.alfa-chemistry.com/product/amrinone-cas-60719-84-8-13957.html
Alichem	22004023	http://www.alichem.com/en/products/216151-27-8.html
Allbio Pharm Co., Ltd	AD03248	http://www.allbiopharm.com/product/n/AD03248
Ambinter	Amb18649580	http://www.ambinter.com/reference/18649580
Angel Pharmatech	AG337888	http://www.angelpharmatech.com/60719-84-8.html
Angene	AGN-PC-0JK6MN	http://www.angenechemical.com/productshow/AGN-PC-0JK6MN.html
Anward	ANW-56874	http://www.anward.com/pro_result/43325
Ark Pharm	AK-99994	http://www.arkpharminc.com/products/60719-84-8.html
Aurora Fine Chemicals LLC	A02.558.326	http://online.aurorafinechemicals.com/info?ID=A02.558.326
Aurum Pharmatech LLC	M-2461	http://www.Aurumpharmatech.com/Product/ProductDetails/M_2461
Avantor Inc	101094-302	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101094-302
Avantor Inc	101096-786	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101096-786
BLD Pharm	BD12830	http://www.bldpharm.com/products/60719-84-8.html
BioChemPartner	BCP12764	http://www.biochempartner.com/60719-84-8-BCP12764
BioSynth	W-105234	https://www.biosynth.com/en/products/life-science/enzyme-substrates-reagents/products/W-105234.html
CSNpharm	CSN10951	https://www.csnpharm.com/products/amrinone.html
Chem Scene	CS-0013064	http://www.chemscene.com/60719-84-8.html
ChemMol	30101988	http://www.chemmol.com/chemmol/30101988.html
ChemMol	49424520	http://www.chemmol.com/chemmol/49424520.html
Chemspace	CSSB00000063426	https://chem-space.com/CSSB00000063426
Clearsynth	CS-T-03714	https://www.clearsynth.com/en/CST03714.html
Combi-Blocks	QA-1160	http://www.combi-blocks.com/cgi-bin/find.cgi?QA-1160
DC Chemicals	DC8957	http://www.dcchemicals.com/product_show-Amrinone.html
Finetech	FT-0601595	http://www.finetechnology-ind.com/prod/detail/pub/60719-84-8.html
Glentham Life Sciences	GP7331	http://www.glentham.com/products/product/GP7331/
Hairui	HR132658	http://www.hairuichem.com/en/product/60719-84-8.html
Lab Network	LN00194482	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00194482
MedChem Express	HY-B1294	https://www.medchemexpress.com/amrinone.html
OChem	822	http://www.ocheminc.com/index.php?act=psearch&pid=719A848
Sigma-Aldrich	A4056_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a4056?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1034308_USP	https://www.sigmaaldrich.com/catalog/product/usp/1034308?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S017497	http://www.sinfoobiotech.com/product/1020895
Smolecule	S518817	http://www.smolecule.com/products/s518817
THE BioTek	bt-259866	https://www.thebiotek.com/product/inhibitors/bt-259866
eNovation Chemicals	D673798	https://www.enovationchem.com/ProductDetails.asp?ProductID=D673798
eNovation Chemicals	D765978	https://www.enovationchem.com/ProductDetails.asp?ProductID=D765978
eNovation Chemicals	D961064	https://www.enovationchem.com/ProductDetails.asp?ProductID=D961064
mcule	MCULE-2781267039	https://mcule.com/MCULE-2781267039/

PubMed

Title	Date	PubMed
Amrinone for refractory cardiogenic shock following chloroquine poisoning.	1991	1774400
[Randomized controlled trial for the effect of amrinone and aprotinin on proinflammatory cytokine release in patients with prosthetic valve replacement during perioperative period].	2001 Jun	12600112
Comparison of enoximone, amrinone, or levosimendan enriched St. Thomas' hospital cardioplegic solutions used for myocardial preservation in isolated guinea pig hearts.	2002	12515045
[Randomized controlled trial for the effect of amrinone and aprotinin on expression leukocyte adhesion molecule in patients with prosthetic valve replacement during perioperative period].	2002 Apr	12575211
Effects of amrinone on bilateral renal ischemia/reperfusion injury.	2002 Jul	12111179
Cyclooxygenase-2 and adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in rat sponge implants.	2002 Mar	12126060
Effects of cAMP modulators on long-chain fatty-acid uptake and utilization by electrically stimulated rat cardiac myocytes.	2002 Nov 1	12093365
Differential effects of amrinone and milrinone upon myocardial inflammatory signaling.	2002 Sep 24	12354747
Possible contribution of acetylamrinone and its enhancing effects on platelet aggregation under shear stress conditions in the onset of thrombocytopenia in patients treated with amrinone.	2003	14698653
[Effect of dexamethasone, aminoguanidin, amrinone on oxygen utilization in endotoxin shock rabbits].	2003 Apr	14754535
The effect of chronic renal failure on phosphodiesterase inhibitor-induced relaxation responses in rabbit cavernosal strips.	2003 Feb 21	12591108
Effects of epinephrine and phosphodiesterase III inhibitors on bupivacaine-induced myocardial depression in guinea-pig papillary muscle.	2003 Jan	12488382
Congenital junctional ectopic tachycardia: presentation and outcome.	2003 Jul 1	16943912
Development of an in vitro model for vascular injury with human endothelial cells.	2004	15057404
Pharmacokinetics and pharmacodynamics of intravenous inotropic agents.	2004	14871156
Cardiac and vascular effects of diltiazem, dobutamine and amrinone, drugs used after myocardial revascularization.	2004 Jun	15264033
Meta-analysis of hemodynamic optimization: relationship to methodological quality.	2005	16356226
The impact of slow rewarming on inotropy, tissue metabolism, and "after drop" of body temperature in pediatric patients.	2005 Jun	16117455
Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery -- a systematic literature review.	2005 Jun	15987381
Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity.	2005 Nov	16236146
Effects of inotropic drugs on mechanical function and oxygen balance in postischemic canine myocardium: comparison of dobutamine, epinephrine, amrinone, and calcium chloride.	2005 Oct	16224144
Bench-to-bedside review: thrombocytopenia-associated multiple organ failure--a newly appreciated syndrome in the critically ill.	2006	17096864
Bench-to-bedside review: hyperinsulinaemia/euglycaemia therapy in the management of overdose of calcium-channel blockers.	2006	16732893
In vivo dilatation of the fetal and postnatal ductus arteriosus by inhibition of phosphodiesterase 3 in rats.	2006	16319452
Alkaline Phosphatases : Structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes.	2006 Jun	18404473
Effect of combining phosphodiesterase III inhibitors with St Thomas Hospital's solution used as transplantation preservative solution in isolated rat hearts.	2006 Jun	16797275
A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts.	2006 Jun	16717301
Contractile responses to selective phosphodiesterase inhibitors following chronic beta-adrenoreceptor activation.	2006 May	16369769
Acute heart failure: inotropic agents and their clinical uses.	2006 Nov	17059376
Coronary bypass grafting using crossclamp fibrillation does not result in reliable reperfusion of the myocardium when the crossclamp is intermittently released: a prospective cohort study.	2006 Nov 21	17118183
Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers.	2006 Oct 1	16990629
Proper use of phosphodiesterase inhibitors according to the situations.	2006 Sep	17037008
[Current approaches to intraoperative diagnosis and treatment of low cardiac output during cardiosurgical operations].	2006 Sep-Oct	17184052
Investigation of binding proteins for anti-platelet agent K-134 by Drug-Western method.	2007 Feb 23	17207464
[Protection of amrinone against lung injury induced by ischemia/reperfusion in rats].	2007 Jun	17582263
Inotropic and chronotropic effects of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives in isolated rat atria.	2008 Apr	18506213
Tadalafil in the treatment of erectile dysfunction.	2008 Dec	19337438
Comparison of the initial hospitalization costs between the patients treated with dobutamine and the patients treated with amrinone for acute decompensated heart failure in a Japanese institute.	2008 Mar	18387066
Labetalol infusion for refractory hypertension causing severe hypotension and bradycardia: an issue of patient safety.	2008 May 27	18505576
The base exchange reaction of NAD+ glycohydrolase: identification of novel heterocyclic alternative substrates.	2008 Nov 15	18835239
Vesnarinone represses the fibrotic changes in murine lung injury induced by bleomycin.	2009	19381349
Effect of nitric oxide/cyclic guanosine mono-phosphate pathway on gallbladder relaxant response in bile duct-ligated guinea pigs.	2009	19246926
Effects of propofol on responses of rat isolated renal arteriole to vasoactive agents.	2009 Aug-Sep	19540932
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.	2009 Dec	19876734
Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates.	2009 Jan	18930951
Effects of amrinone in an experimental model of hepatic ischemia-reperfusion injury.	2009 Jan	18468627
Evaluation of preoperative intra-aortic balloon pump in coronary patients with severe left ventricular dysfunction undergoing OPCAB surgery: early and mid-term outcomes.	2009 Jul 27	19635155
The role of phosphodiesterase 3 in endotoxin-induced acute kidney injury.	2009 Jun 1	19486524
Pharmacological interventions for ischaemia reperfusion injury in liver resection surgery performed under vascular control.	2009 Oct 7	19821445
Pharmacological interventions versus no pharmacological intervention for ischaemia reperfusion injury in liver resection surgery performed under vascular control.	2009 Oct 7	19821421

Patents

Sample Use Guides

In Vivo Use Guide

Congestive heart failure IV Initially, 0.75 mg/kg as a slow (over 2–3 minutes) direct injection; if warranted, may administer a supplemental direct IV dose of 0.75 mg/kg 30 minutes after the initial dose.1 60 Direct IV injection is followed by an IV infusion of 5–10 mcg/kg per minute. Duration of therapy determined by clinical response and tolerance to adverse effects.

Route of Administration: Intravenous

In Vitro Use Guide

Inamrinone inhibited human platelet aggregation at 10,800 s(-1) in a dose-dependent manner with the IC(50) value of 61 +/- 8 uM (mean +/- S.D.), Inamrinone significantly inhibited platelet aggregation at 1200 s(-1) only at highest concentration tested (100 uM)

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:21:23 GMT 2023` Edited by `admin` on `Fri Dec 15 16:21:23 GMT 2023`
Record UNII	I229274Y5B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

INAMRINONE LACTATE

Common Name

English

Amrinone lactate [WHO-DD]

Common Name

English

INOCOR

Brand Name

English

INAMRINONE LACTATE [ORANGE BOOK]

Common Name

English

PROPANOIC ACID, 3-HYDROXY-, COMPD. WITH 5-AMINO(3,4'-BIPYRIDIN)-6(1H)-ONE

Common Name

English

INAMRINONE LACTATE [VANDF]

Common Name

English

5-AMINO(3,4'-BIPYRIDIN)-6(1H)-ONE LACTATE

Systematic Name

English

AMRINONE LACTATE [MART.]

Common Name

English

AMRINONE LACTATE

Common Name

English

AMRINONE LACTATE [VANDF]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C744